Form 4: Spyre Therapeutics CEO Sells $632K in Stock

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock for approximately $632,866 through a pre-arranged 10b5-1 trading plan.

Summary

• Cameron Turtle, CEO and Director of Spyre Therapeutics, Inc. (SYRE), sold a total of 15,000 shares of common stock.
• The sales occurred on March 2, 2026, under a Rule 10b5-1 trading plan adopted on June 20, 2025.
• One block of 5,900 shares was sold at a weighted average price of $41.73, with prices ranging from $41.23 to $42.19.
• Another block of 9,100 shares was sold at a weighted average price of $42.49, with prices ranging from $42.23 to $42.93.
• Following these transactions, Cameron Turtle beneficially owns 642,540 shares of Spyre Therapeutics common stock.
• This remaining ownership includes 130,683 shares that vest in monthly installments through November 2026, contingent on his continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can be perceived negatively, the execution under a 10b5-1 plan suggests a pre-planned financial management decision rather than a reaction to new company-specific information.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned liquidity event rather than an immediate reaction to negative company news.

Negatives

• An insider sale by the CEO, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider sales, particularly by a CEO, are closely watched by the market. While a 10b5-1 plan mitigates the immediate negative signal, investors often scrutinize the timing and magnitude of such sales, especially in the biotechnology sector where executive confidence is a key sentiment driver.

Comparison to Industry Standards

• Insider sales are common across all industries, including biotechnology.
• The use of a Rule 10b5-1 plan aligns with best practices for executives to manage personal finances while avoiding accusations of trading on material non-public information.
• Compared to other biotech CEOs, a sale of 15,000 shares, representing a small fraction of the CEO's total holdings (642,540 shares remaining), is not an unusually large divestment, especially given the pre-planned nature.

Stakeholder Impact

• Shareholders: May interpret the CEO's sale as a slight reduction in insider confidence, though the 10b5-1 plan mitigates this. The remaining significant holding still aligns the CEO's interests with shareholders.

Key Dates

Recommendation

The CEO's sale of shares was conducted under a pre-arranged 10b5-1 plan, which typically indicates a planned personal financial event rather than a reaction to new material information. While any insider sale warrants attention, this particular transaction does not provide a strong signal for either buying or selling the stock. The CEO retains a substantial holding, including a significant portion of unvested shares, suggesting continued alignment with the company's long-term performance. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates from Spyre Therapeutics.

Keywords

Spyre Therapeutics, SYRE, Cameron Turtle, Insider Sale, Form 4, Stock Transaction, CEO, 10b5-1 Plan, Equity Ownership